A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped GSK confirmed misrepresentation of preclinical data that supported the rationale for GSK2618960 in MS. This decreased benefit assessment for MS

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG: Part A: 100 mg/mL GSK2618960
DRUG: Part A: matching placebo
DRUG: Part B: Dose of GSK2618960 decided from Part A
DRUG: Part B: matching placebo
DRUG: Part C: Dose of GSK2618960 decided from Part A and B

Sponsor

GlaxoSmithKline